ArticleProceedings of the National Academy of Sciences of the United States of America2013
Direct production of mouse disease models by embryo microinjection of TALENs and oligodeoxynucleotides.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.
- 2015 Guidelines for Establishing Genetically Modified Rat Models for Cardiovascular Research.Journal of cardiovascular translational research · 2015Guideline
- Mechanistic toxicology in light of genetic compensation.Toxicological sciences : an official journal of the Society of Toxicology · 2024Article
- An analgesic pathway from parvocellular oxytocin neurons to the periaqueductal gray in rats.Nature communications · 2023Article
- Review
- Stem Cell-Based Therapeutic Approaches in Genetic Diseases.Advances in experimental medicine and biology · 2023Article
- Establishment of an integrated automated embryonic manipulation system for producing genetically modified mice.Scientific reports · 2021Article
- Advances in Genome Editing and Application to the Generation of Genetically Modified Rat Models.Frontiers in genetics · 2021Review
- Principles of Genetic Engineering.Genes · 2020Review
- Adenovirus vectors in hematopoietic stem cell genome editing.FEBS letters · 2019Review
- An overview of OECD activities related to modern techniques of biotechnology and genome editing : OECD conference on genome editing, June 2018.Transgenic research · 2019Article
- Non-Viral Delivery To Enable Genome Editing.Trends in biotechnology · 2019Review
- Gene-edited CRISPy Critters for alcohol research.Alcohol (Fayetteville, N.Y.) · 2019Review
- High Efficiency Targeting of Non-coding Sequences Using CRISPR/Cas9 System in Tilapia.G3 (Bethesda, Md.) · 2019Article
- Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy.Computational and structural biotechnology journal · 2019Review
- HDAd5/35Molecular therapy. Methods & clinical development · 2018Article
- Transplantation of Gene-Edited Hepatocyte-like Cells Modestly Improves Survival of Arginase-1-Deficient Mice.Molecular therapy. Nucleic acids · 2018Article
- Alcohol reduces muscle fatigue through atomistic interactions with nicotinic receptors.Communications biology · 2018Article
- Relaxed chromatin induced by histone deacetylase inhibitors improves the oligonucleotide-directed gene editing in plant cells.Journal of plant research · 2018Article
- The contribution of homology arms to nuclease-assisted genome engineering.Nucleic acids research · 2017Article
- Targeted RP9 ablation and mutagenesis in mouse photoreceptor cells by CRISPR-Cas9.Scientific reports · 2017Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study of genetic disease mechanisms relies mostly on targeted mouse mutants that are derived from engineered embryonic stem (ES) cells. Nevertheless, the establishment of mutant ES cells is laborious and time-consuming, restricting the study of the increasing number of human disease mutations discovered by high-throughput genomic analysis. Here, we present an advanced approach for the production of mouse disease models by microinjection of transcription activator-like effector nucleases (TALENs) and synthetic oligodeoxynucleotides into one-cell embryos. Within 2 d of embryo injection, we created and corrected chocolate missense mutations in the small GTPase RAB38; a regulator of intracellular vesicle trafficking and phenotypic model of Hermansky-Pudlak syndrome. Because ES cell cultures and targeting vectors are not required, this technology enables instant germline modifications, making heterozygous mutants available within 18 wk. The key features of direct mutagenesis by TALENs and oligodeoxynucleotides, minimal effort and high speed, catalyze the generation of future in vivo models for the study of human disease mechanisms and interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.